Pichia pastoris engineered strain for producing recombinant antigen of SARS-cov-2, preparation method therefor, and use thereof

By modifying Pichia cerevisiae strains, the problem of uneven glycosylation in the yeast cell expression system was solved, efficient, uniform expression and secretion of the RBD dimer antigen of the new coronavirus was achieved, and broad-spectrum vaccine development of the new coronavirus vaccine was promoted.

WO2024230722A1PCT designated stage expired Publication Date: 2024-11-14INST OF MICROBIOLOGY CHINESE ACAD OF SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/091667
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The uneven glycosylation of the recombinant protein of the new coronavirus in the existing yeast cell expression system has affected the industrialization process of vaccines and is costly and difficult to produce on a large scale.

Method used

By knocking out the α-1,6-mannose transferase gene in Pichia cerevisiae and replenishing histidine-deficient type, a glycosylation-improved Pichia strain was constructed, and the S protein RBD of the new coronavirus was introduced based on it. The coding sequence of the antigen achieves efficient expression and secretion of the new coronavirus RBD dimer antigen.

Benefits of technology

A high-level and uniform expression and secretion of the new coronavirus RBD dimer antigen has been achieved, which can induce high-level neutralizing antibodies, has the potential of a broad-spectrum vaccine, and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024091667-FTAPPB-I100001
    Figure PCTCN2024091667-FTAPPB-I100001
  • Figure PCTCN2024091667-FTAPPB-I100002
    Figure PCTCN2024091667-FTAPPB-I100002
  • Figure PCTCN2024091667-FTAPPB-I100003
    Figure PCTCN2024091667-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a modified Pichia pastoris strain and a preparation method therefor, a recombinant Pichia pastoris engineered strain, based on the modified Pichia pastoris strain, expressing a SARS-CoV-2 antigen, a preparation method therefor, and a use thereof, and a method for preparing a SARS-CoV-2 recombinant protein vaccine. A modified Pichia pastoris expression vector can not only express and secrete recombinant proteins at a high level, but also enable the expressed recombinant proteins to retain a core glycosylation modification. Glycoproteins secreted thereby have good uniformity. The recombinant Pichia pastoris engineered strain, based on the Pichia pastoris expression vector, expressing the SARS-CoV-2 antigen can produce, in a highly efficient manner, high-quality RBD dimer antigens having uniform glycosylation. The produced RBD dimer antigens can be used as immunogens to induce the production of high-level neutralizing antibodies against a SARS-CoV-2 prototype strain and variants thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Pichia pastoris engineered bacteria for producing novel coronavirus recombinant antigens, preparation method, and application thereof

[0001] Cross-references

[0002] This application claims priority to the Chinese patent application filed on May 8, 2023, with application number 202310513084.8 and invention name “Pichia pastoris engineered bacteria for producing recombinant novel coronavirus antigens, preparation methods and applications thereof”, the entire contents of which are incorporated herein by reference. Technical Field

[0003] This application belongs to the field of bioengineering technology, and specifically relates to an engineered Pichia pastoris for producing a recombinant antigen of a novel coronavirus, its preparation method, and its application in the preparation of a novel coronavirus vaccine. Background Art

[0004] Novel coronavirus infection (also known as COVID-19, formerly known as novel coronavirus pneumonia) is an acute respiratory infectious disease caused by the novel coronavirus (also known as SARS-CoV-2). The novel coronavirus belongs to the genus Betacoronavirus in the family Coronaviridae and is a positive-stranded RNA enveloped virus. The spike (S) protein on the surface of the novel coronavirus envelope plays a vital role in viral invasion. The S protein consists of S1 and S2 subunits. The receptor binding domain (RBD) of the S1 subunit is responsible for binding to the viral receptor protein ACE2 (Angiotensin-converting enzyme 2), while the S2 subunit is responsible for mediating membrane fusion. Therefore, the S protein, especially the RBD, is an important target for designing a novel coronavirus vaccine. In the early stages of the COVID-19 pandemic, the Institute of Microbiology, Chinese Academy of Sciences, developed a recombinant subunit protein vaccine, ZF2001, based on the SARS-CoV-2 RBD dimer using a mammalian cell expression system. In subsequent clinical trials, the vaccine demonstrated good immunogenicity and protective efficacy, and has been widely used and promoted both domestically and internationally, becoming a mainstay of COVID-19 prevention and control.

[0005] In experimental research on recombinant proteins, compared with mammalian cell expression systems, the production of recombinant proteins using yeast cell expression systems has the characteristics of low cost and high production capacity. Therefore, yeast cells have become one of the important eukaryotic expression hosts for industrial production of protein products.

[0006] Pichia pastoris is a typical yeast strain with advantages such as high expression level, low culture cost, simple molecular manipulation, easy to obtain stable genetic strains, and large-scale production. It has been used in the production of vaccines such as hepatitis B vaccine. In the Pichia pastoris expression system, protein expression has two expression modes: intracellular expression and secretory expression. Among them, secretory expression has become the preferred protein expression mode due to its simple protein acquisition process and low cost. Proteins will undergo post-translational modification during the secretion process, among which glycosylation modification is a very important aspect. Yeast cell secretory proteins often have heterogeneous polymannan modifications, especially proteins containing multiple N-glycosylation sites, which seriously hinders the industrialization process of yeast vaccines. Therefore, the development of Pichia pastoris engineered strains with improved glycosylation has become one of the breakthroughs in solving this problem and is also one of the current focuses in the field of protein expression.

[0007] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the application and should not be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0008] Summary of the Invention

[0009] Purpose of the Invention

[0010] In response to the defects in the above-mentioned prior art, the purpose of this application is to provide a modified Pichia pastoris strain and a preparation method thereof, a recombinant Pichia pastoris engineered bacterium expressing a novel coronavirus antigen based on the modified Pichia pastoris strain and its preparation method and use, as well as a method for preparing a recombinant protein vaccine for the novel coronavirus.

[0011] Solution

[0012] To achieve the purpose of this application, this application provides the following technical solutions:

[0013] In a first aspect, the present application provides a modified Pichia pastoris strain (hereinafter also referred to as GSΔoch1pAO strain), which is obtained by knocking out the α-1,6-mannosyltransferase gene and complementing the histidine deficiency on the basis of the Pichia pastoris GS115 strain.

[0014] The modified Pichia pastoris strain can be obtained by the following method:

[0015] By genetic engineering methods well known to those skilled in the art, the α-1,6 mannosyltransferase gene (ie, OCH1 gene) in the Pichia pastoris GS115 strain is knocked out, and then a histidinol dehydrogenase coding sequence is introduced therein to complement the histidine deficiency.

[0016] In a second aspect, the present application provides a method for preparing the modified Pichia pastoris strain as described in the first aspect above, characterized in that the preparation method comprises the following steps:

[0017] (1) By genetic engineering, the α-1,6-mannosyltransferase gene in Pichia pastoris GS115 was knocked out to obtain the GSΔoch1 strain;

[0018] (2) After linearizing the exogenous histidinol dehydrogenase expression plasmid, the plasmid was integrated into the GSΔoch1 strain to obtain the modified Pichia pastoris strain.

[0019] Preferably, the exogenous histidinol dehydrogenase expression plasmid is an expression plasmid comprising a histidinol dehydrogenase gene (HIS4) in the vector pAOαM, for example, a recombinant expression plasmid as shown in SEQ ID NO:10.

[0020] In a third aspect, the present application provides a recombinant Pichia pastoris engineered bacterium, which is obtained by introducing the coding sequence of the SARS-CoV-2 S protein RBD antigen into the modified Pichia pastoris strain as described in the first aspect above.

[0021] In a preferred embodiment, the SARS-CoV-2 S protein RBD antigen is a homozygous or chimeric dimer of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variant strain; wherein, the SARS-CoV-2 variant strain is selected from: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Omicron subtype BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, BA.4, BA.5, BQ.1.1, XBB.

[0022] In a preferred embodiment, the novel coronavirus S protein RBD antigen is a dimer formed by amino acid fragments 329-537 of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variants through a linker or directly connected in series, preferably a dimer formed by directly connected in series;

[0023] Further preferably, the novel coronavirus S protein RBD antigen is a dimer formed by directly connecting amino acid fragments 329-537 of the S protein RBD region of the prototype strain and the prototype strain (ie, prototype-prototype), the prototype strain and the Beta variant (ie, prototype-Beta), the Beta variant and the Delta variant (ie, Beta-Delta), the Delta variant and the Omicron variant (including Delta-Omicron BA.1, Delta-Omicron BA.4, Delta and Omicron BA.5, Delta-Omicron XBB, Delta-Omicron BQ.1.1), or the Omicron variant and the Omicron variant (for example, Omicron XBB-Omicron BQ.1.1, Omicron XBB-Omicron BA.5);

[0024] More preferably, the novel coronavirus S protein RBD antigen is selected from:

[0025] (1) a dimer formed by directly connecting amino acid fragments 329-537 of the RBD region of the S protein of the prototype strain and the Beta variant, the amino acid sequence of which is shown in SEQ ID NO: 1, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 2;

[0026] (2) a dimer formed by directly concatenating the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.1, the amino acid sequence of which is shown in SEQ ID NO: 3, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 4;

[0027] (3) a dimer formed by directly concatenating the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.5, the amino acid sequence of which is shown in SEQ ID NO: 11, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 12;

[0028] (4) a dimer formed by directly concatenating the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron BQ.1.1, the amino acid sequence of which is shown in SEQ ID NO: 13, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 14;

[0029] (5) a dimer formed by directly concatenating the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron XBB, the amino acid sequence of which is shown in SEQ ID NO: 15, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 16;

[0030] (6) A dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Omicron XBB and Omicron BA.5 in series, the amino acid sequence of which is shown in SEQ ID NO: 17, preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO: 18.

[0031] In a fourth aspect, the present application provides a method for preparing the recombinant Pichia pastoris engineered bacteria as described in the third aspect above, the preparation method comprising the following steps:

[0032] The coding sequence of the SARS-CoV-2 S protein RBD antigen is cloned into a Pichia pastoris expression vector to obtain a recombinant expression plasmid; the obtained recombinant expression plasmid is linearized and then transferred into the modified Pichia pastoris strain as described in claim 1 to obtain the recombinant Pichia pastoris engineered bacteria.

[0033] Preferably, the Pichia pastoris expression vector comprises the following elements: a promoter, an α-mating factor signal, a Kex2 protease recognition site, a multiple cloning site, a C-terminal His tag, and a terminator; optionally, the promoter is an AOX promoter; optionally, the terminator is an AOX terminator;

[0034] Further preferably, the Pichia pastoris expression vector is selected from: Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα, pPICZαA, pPICZαB, pPICZαC, pPIC9K, PichiaPink TM In a specific embodiment, the Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα is used as the Pichia pastoris expression vector, and the nucleic acid sequence of the pMPICZα is shown in SEQ ID NO:5.

[0035] Alternatively, the linearized recombinant expression plasmid is transformed into the modified Pichia pastoris strain according to claim 1 by electroporation;

[0036] In a preferred embodiment, the preparation method comprises:

[0037] 1) cloning the coding sequence of the novel coronavirus S protein RBD antigen into a Pichia pastoris expression vector, preferably an Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα, to obtain a recombinant expression plasmid;

[0038] 2) linearizing the recombinant expression plasmid obtained in step 1) by enzyme digestion;

[0039] 3) preparing competent cells of the modified Pichia pastoris strain according to claim 1;

[0040] 4) The linearized recombinant expression plasmid obtained in step 2) is transformed into the competent cells obtained in step 3) by electroporation to obtain the recombinant Pichia pastoris engineered bacteria.

[0041] In the fifth aspect, the present application provides the use of the recombinant Pichia pastoris engineered bacteria as described in the third aspect above in the preparation of a recombinant protein vaccine for the new coronavirus.

[0042] In the sixth aspect, the present application provides a method for preparing a recombinant protein vaccine of the new coronavirus, the method comprising: fermenting and culturing the recombinant Pichia pastoris engineered bacteria as described in the third aspect above, collecting the supernatant, and isolating the expressed new coronavirus S protein RBD antigen therefrom. Beneficial effects

[0043] The inventors of the present application constructed a glycosylation-modified Pichia pastoris strain by knocking out the α-1,6-mannosyltransferase gene and complementing the histidine deficiency, and provided a recombinant Pichia pastoris engineered bacterium expressing a novel coronavirus antigen based on the Pichia pastoris expression vector.

[0044] The glycosylation-modified Pichia pastoris expression vector provided in the present application can not only express and secrete recombinant proteins at a high level, but also enable the expressed recombinant proteins to retain the core glycosylation modifications, and the secreted glycoproteins have good uniformity; furthermore, the recombinant Pichia pastoris engineered bacteria expressing the new coronavirus antigen based on the Pichia pastoris expression vector provided in the present application can produce a new coronavirus RBD dimer antigen with more uniform glycosylation at a higher yield. The produced new coronavirus RBD dimer antigen has high quality and can be used as a vaccine to induce the production of high levels of neutralizing antibodies against the prototype strain of the new coronavirus and a series of variant strains, and is expected to become a broad-spectrum vaccine for preventing the new coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] One or more embodiments are exemplarily illustrated by the accompanying figures, and these exemplary illustrations do not limit the embodiments. The word "exemplary" is used herein to mean "serving as an example, example, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as superior or preferred over other embodiments.

[0046] Figure 1 shows the absorbance curve of the eluate of the RBD dimer proteins PP0 and PB0 purified by nickel affinity column and subjected to molecular sieve chromatography (to further purify the protein) as described in Example 3 of the present application, as well as the SDS-PAGE identification results of the collected elution peaks; wherein the arrows on the absorbance curve indicate the elution peaks of PP0 and PB0, respectively.

[0047] Figure 2 shows the growth curve of the engineered strain GSΔoch1-PB0-His described in Example 5 of the present application and the expression of RBD dimer protein in its 72h fermentation broth detected by Western blot.

[0048] FIG3 shows the growth curve of the engineered strain GSΔoch1pAO-PB0-His described in Example 8 of the present application and the expression of RBD dimer protein in its 72 h fermentation broth detected by Western blot.

[0049] Figure 4 shows the absorbance curve of the eluate of the RBD dimer protein PB0 purified by nickel affinity column and subjected to molecular sieve chromatography (to further purify the protein) as described in Example 9 of the present application, as well as the SDS-PAGE identification results of the collected elution peaks.

[0050] Figure 5A shows the construction design of the six RBD dimer proteins described in Example 10 of the present application; Figure 5B shows the expression of RBD dimer proteins in the fermentation broth detected by Western blot after 72 hours of shake flask fermentation of the recombinant engineered strain containing six RBD dimer proteins described in Example 11 of the present application.

[0051] Figure 6 shows the absorbance curve of the eluate of the RBD dimer protein PB purified by nickel affinity column and subjected to molecular sieve chromatography (to further purify the protein) as described in Example 12 of the present application, as well as the SDS-PAGE identification results of the collected elution peak; wherein the arrow indicates the elution peak of the PB protein and the SDS-PAGE identification results of the elution peak.

[0052] Figure 7 shows the absorbance curve of the eluate of the RBD dimer protein D-BA.1 purified by nickel affinity column and subjected to molecular sieve chromatography (to further purify the protein) as described in Example 13 of the present application, as well as the SDS-PAGE identification results of the collected elution peak; wherein, the arrow indicates the elution peak of the D-BA.1 protein and the SDS-PAGE identification results of the elution peak.

[0053] Figure 8 shows the results of antibody level detection in the serum collected from mice after the second immunization and the third immunization with the immunogen as described in Example 14 of the present application.

[0054] Figure 9 shows the neutralization titer results of the serum collected from mice after the third immunization with the immunogen, as recorded in Example 15 of the present application, against the pseudovirus of the prototype strain of the new coronavirus and a series of variant strains.

[0055] Figure 10 shows the SDS-PAGE identification results of the RBD dimer protein D-BA.5 purified by nickel affinity column as described in Example 16 of the present application.

[0056] Figure 11 shows the SDS-PAGE identification results of the RBD dimer protein D-BQ.1.1 purified by nickel affinity column as described in Example 17 of the present application.

[0057] FIG12 shows the SDS-PAGE identification results of the RBD dimer protein D-XBB purified by nickel affinity column as described in Example 18 of the present application.

[0058] Figure 13 shows the SDS-PAGE identification results of the RBD dimer protein XBB-BA.5 purified by nickel affinity column as described in Example 19 of the present application.

[0059] Figure 14 shows the results of detecting specific binding antibody levels in the serum collected from mice after the second immunization and the serum collected after the third immunization with the immunogen as described in Example 20 of the present application.

[0060] Figure 15 shows the results of neutralizing antibody titer detection against the prototype strain of the new coronavirus and a series of pseudovirus variants in the serum collected from mice after the third immunization with the immunogen, as recorded in Example 21 of the present application.

[0061] Figure 16 shows the neutralization titer test results of the sera collected from mice at the 2nd week (corresponding to "8w" in the figure) and the 16th week (corresponding to "22w" in the figure) after the third immunization with the immunogen, as recorded in Example 22 of the present application, against the pseudovirus of the prototype strain of the new coronavirus and a series of variant strains.

[0062] Figure 17 shows the neutralization titer results of the pseudovirus of the prototype strain of the new coronavirus, which was obtained from sera collected from mice 2 weeks and 16 weeks after immunization with two doses of inactivated vaccine, as recorded in Example 23 of the present application.

[0063] Figure 18 shows the neutralization titer results of the sera collected from mice after the yeast-expressed dimer vaccine booster injection of the present application, as recorded in Example 23 of the present application, against the pseudovirus of the prototype strain of the new coronavirus and a series of variant strains.

[0064] Figure 19 shows the neutralization titer results of the sera collected from mice 2 weeks after the third immunization with the immunogen, as recorded in Example 24 of the present application, against the pseudovirus of the prototype strain of the new coronavirus and a series of variant strains.

[0065] Figure 20 shows the neutralization titer results of the pseudovirus of the new coronavirus variant EG.5, which was collected from mice 3 days before infection (i.e., 8 weeks after the third immunization) as recorded in Example 24 of the present application.

[0066] Figure 21 shows the qPCR assay results of gRNA and sgRNA of EG.5 virus in the lung tissue of mice after challenge, as described in Example 25 of the present application.

[0067] Figure 22 shows the lung tissue section results of mice after challenge with poison as described in Example 26 of the present application.

[0068] FIG23 shows a schematic diagram of the electron microscopic structure of the complex of the PB protein and CB6 Fab protein purified in Example 12, as described in Example 27 of the present application.

[0069] Figure 24 shows the mass spectrometry identification results of the N-sugar side chains of the PBO protein purified in Example 3 of the present application and the PB protein purified in Example 12, as determined in Example 28.

[0070] Figure 25 shows the statistical results of the N-sugar side chain distribution of the PBO protein purified in Example 3 of the present application and the PB protein purified in Example 12, as determined in Example 28. DETAILED DESCRIPTION

[0071] To make the purpose, technical solutions, and advantages of the embodiments of this application more clear, the technical solutions in the embodiments of this application will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of this application, not all of them. Based on the embodiments of this application, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of this application.

[0072] In addition, in order to better illustrate the present application, numerous specific details are provided in the following detailed description. It should be understood by those skilled in the art that the present application can be implemented without certain specific details. In some embodiments, raw materials, components, methods, means, etc. well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present application.

[0073] Unless expressly stated otherwise, throughout the specification and claims, the term "comprise" or variations such as "include" or "comprising", etc., will be understood to include the stated elements or components but not to exclude other elements or other components.

[0074] In the following examples, the following general methods are involved.

[0075] Preparation of Pichia pastoris competent cells

[0076] The Pichia pastoris strain was inoculated into 50 ml of YPD medium (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose) and cultured at 30°C and 220 r / min until the OD 600 =1.3-1.5; centrifuge at 4°C and 5000g for 5 min to collect the cells; add 9 mL of pre-cooled BEDS and 1 mL of 1 M DTT to the collected cells, resuspend and mix, centrifuge at 4°C and 5000g for 5 min to collect the cells, add 1 mL of pre-cooled BEDS to resuspend the cells, and obtain electroporation competent cells.

[0077] Shake flask fermentation induction of recombinant strains

[0078] Two single clones of the recombinant Pichia pastoris strain were randomly selected and inoculated into 5 mL YPD liquid medium. The culture was shaken at 30°C and 220 r / min for 48 h, centrifuged at 3000 r / min for 5 min, and the supernatant was discarded. The collected bacteria were transferred to 25 mL BMMY induction medium (containing 10 g / L yeast extract and 20 g / L peptone, sterilized at 121°C for 20 min, and then 13.4 g / L YNB and 4 × 10 -4 Incubate in a shaking incubator (0.5% methanol, 0.5% biotin, 0.5% methanol) at 30°C and 220 rpm. Add 0.5%-0.8% (v / v) methanol every 12 hours. Samples are collected regularly, centrifuged, and the supernatant is analyzed for protein expression. If the strain is histidine-deficient, supplement BMMY medium with 0.04 mg / mL histidine.

[0079] High-density fermentation induction of recombinant strains

[0080] Seed shake flask culture: Add 200 μL of bacterial solution from the glycerol tube to 5 mL of YPD. After culturing for 12 h, inoculate 1% of the inoculum into 50 mL of YPD medium and culture at 30°C and 220 rpm for 24 h.

[0081] High-density fermentation culture: BMGY (containing 10 g / L yeast extract, 20 g / L peptone, 40 g / L glycerol) was sterilized at 115°C for 20 min, and then 13.4 g / L YNB, 4×10 -4 A 1L fully automated fermenter was inoculated with a 6% inoculum of a 1000-gram biotin (g / L biotin) solution. The pH was controlled at 6.0 with ammonia, the temperature at 30°C, the agitation speed at 600-950 rpm, and the aeration rate at 2 vvm. When the glycerol was depleted (dissolved oxygen levels increased rapidly), methanol was added after starvation for 0.5-1.5 hours to induce recombinant protein expression. Methanol was maintained at 3 g / L in the tank using an automated feed system.

[0082] Example 1. Design of RBD dimer expression vector suitable for Pichia pastoris expression system

[0083] In the following examples, the Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα (whose nucleic acid sequence is shown in SEQ ID NO: 5) was used as a vector to construct an expression plasmid for the SARS-CoV-2 RBD dimer antigen.

[0084] The expression vector pMPICZα contains the coding sequences for the AOX promoter, α-mating factor signal, Kex2 protease recognition site, multiple cloning site, C-terminal His tag, and AOX terminator. During construction, the SARS-CoV-2 RBD dimer fragment was ligated into the multiple cloning site of the pMPICZα vector using XhoI / NotI double digestion to complete the vector construction. To facilitate the acquisition of the RBD dimer protein, a 6xHis purification tag was designed at the C-terminus of the protein. Furthermore, the nucleotide sequence of the RBD dimer protein was codon-optimized to account for the codon preference of Pichia pastoris.

[0085] Sequence synthesis and vector construction were completed by Nanjing GenScript.

[0086] Example 2. Construction of yeast strains expressing SARS-CoV-2 prototype strain RBD dimer and prototype-Beta chimeric RBD dimer protein based on wild-type Pichia pastoris

[0087] 1. Preparation of Pichia pastoris competent cells

[0088] According to the above-mentioned procedure of “Preparation of Pichia pastoris competent cells”, Pichia pastoris competent cells for electroporation were prepared using Pichia pastoris strain GS115 (Invitrogen, Ca. 18100).

[0089] 2. Electroporation of recombinant expression plasmid into Pichia pastoris competent cells

[0090] According to the method of Example 1, recombinant expression plasmids of the SARS-CoV-2 prototype strain RBD dimer (dimer of the RBD segment at positions 320-537, abbreviated as PPO) and the prototype-Beta chimeric RBD dimer (dimer of the RBD segment at positions 320-537, abbreviated as PB0) were constructed, namely pMPICZα-PP0-His and pMPICZα-PB0-His, respectively; wherein the amino acid sequence of the RBD dimer of PP0 is shown in SEQ ID NO: 6, and its encoding nucleic acid sequence is shown in SEQ ID NO: 7; the amino acid sequence of the RBD dimer of PB0 is shown in SEQ ID NO: 8, and its encoding nucleic acid sequence is shown in SEQ ID NO: 9.

[0091] Take about 4 μg of the correctly constructed recombinant expression plasmids pMPICZα-PP0-His and pMPICZα-PB0-His, linearize them by SacI enzyme digestion, and recover the linearized DNA fragments using a gel recovery kit; mix the linearized DNA with 40 μL of GS115 competent cells prepared in step 1, and transfer them to a pre-cooled 0.2 cm electroporation cup; use an electroporator from BIO-RAD, USA, and perform electroporation according to the Pichia parameters preset for the electroporation cup; after the electroporation, immediately add 1 mL of pre-cooled 1 M sorbitol aqueous solution to the electroporation cup, and then transfer all the solution in the electroporation cup to a sterile centrifuge tube, incubate at 30°C for 1 hour, spread on a YPD plate supplemented with 100 μg / mL bleomycin, and culture inverted at 30°C for 2-4 days until colonies appear.

[0092] Thus, the recombinant Pichia pastoris strains GS-PPO-His and GS-PB0-His containing the coding gene of the above-mentioned RBD dimer protein were obtained.

[0093] Example 3. Expression and Acquisition of Dimeric Proteins of GS-PPO-His and GS-PB0-His from Wild-Type Pichia Pastoris Recombinant Yeast Strain

[0094] According to the above-mentioned “High-density fermentation induction of recombinant strains” procedure, the recombinant Pichia pastoris strains GS-PP0-His and GS-PB0-His constructed in Example 2 were induced by high-density fermentation; after 90 h of methanol-induced expression, the fermentation was terminated, the precipitate was removed by centrifugation, and the supernatant was filtered through a 0.22 μm filter membrane to further remove impurities; the resulting cell supernatant was adsorbed on a nickel affinity column (His Trap, GE Healthcare) at 4°C and washed with buffer A (8 mM Na2HPO4, 136 mM NaCl, 2 mM KH2PO4, 2.6 mM KCl, pH 7.4) to remove non-specific binding proteins, and then the target protein was eluted from the His Trap with buffer B (8 mM Na2HPO4, 136 mM NaCl, 2 mM KH2PO4, 2.6 mM KCl, 300 mM imidazole), and the eluate at the elution peak was collected for subsequent molecular sieve chromatography and SDS-PAGE identification of the target protein.

[0095] The eluate collected at the elution peak was concentrated using a 10 kD concentrator and exchanged with molecular sieve chromatography buffer (PBS (8 mM Na2HPO4, 136 mM NaCl, 2 mM KH2PO4, 2.6 mM KCl, pH 7.4)) to a final volume of less than 1 ml. The target protein was further purified by molecular sieve chromatography using a HiLoad™ 16 / 600 Superdex™ 200 pg column (GE Healthcare). During the chromatography process, the eluate at the elution peak was collected for SDS-PAGE identification of the target protein.

[0096] The molecular sieve chromatography curves of the RBD dimer proteins PP0 and PB0 and the SDS-PAGE identification results of their elution peaks are shown in Figure 1 ; in the molecular sieve chromatography curves of PP0 and PB0 in Figure 1 , the arrows indicate the elution peaks corresponding to the target proteins; in the SDS-PAGE identification results of the elution peaks in Figure 1 , the SDS-PAGE electrophoresis results of the target protein eluates with or without the addition of PNGaseF deglycosylase are shown above the lanes, which show that in the target protein eluate without the addition of PNGaseF deglycosylase, the eluted proteins PP0 and PB0 are both diffuse, suggesting that the expressed dimer proteins PP0 and PB0 are not uniform; however, after the addition of PNGaseF deglycosylase, the protein band is single and the size is also that of a dimer, indicating that the heterogeneity of the purified dimer protein is mainly due to heterogeneous glycosylation modification; that is, the RBD dimer protein expressed in the wild-type Pichia pastoris expression system has the defect of heterogeneous glycosylation modification.

[0097] Example 4. Construction of a recombinant yeast strain of SARS-CoV-2 PB0 based on the glycosylation engineered strain GSΔoch1

[0098] In yeast, polymannan synthesis is catalyzed by a variety of glycosidases, among which the α-1,6-mannan transferase encoded by the gene OCH1 is responsible for initiating the polymannan synthesis. In this example, the och1 gene of the Pichia pastoris strain GS115 was deleted according to the method described in the literature (Enhancement of the Gene Targeting Efficiency of Non-Conventional Yeasts by Increasing Genetic Redundancy, PLoS ONE, 2013) to construct the GSΔoch1 strain.

[0099] According to the above-mentioned “Preparation of Pichia pastoris competent cells” procedure, competent cells of the GSΔoch1 strain were prepared; and, according to the procedure described in Example 2, a recombinant expression plasmid of SARS-CoV-2 PB0 (whose amino acid sequence and encoding nucleic acid sequence are the same as those described in Example 2) was prepared, linearized, and electroporated into the competent cells of the GSΔoch1 strain to obtain the engineered strain of GSΔoch1-PB0-His.

[0100] Example 5. Shake flask fermentation induction and protein expression detection of GSΔoch1-PB0-His engineered strain

[0101] According to the above-mentioned "shake flask fermentation induction of recombinant strains" procedure, two single clones of the engineered strain GSΔoch1-PB0-His constructed in Example 4 were randomly selected and inoculated into BMMY medium to induce protein expression. Samples were taken every 24 h, and the OD value of the bacterial solution at 600 nm (i.e., OD 600 ), the strain growth curve is shown in Figure 2; at the same time, the fermentation broth was collected after 72 hours, the supernatant was collected, and the expression of the target protein was detected by Western blot. Among them, the primary antibody was a complete antibody isolated from the immunized rabbit serum using the monomeric protein of the SARS-CoV-2 prototype strain RBD (319-537) derived from mammalian cells 293F. The secondary antibody was an HRP-labeled anti-rabbit antibody. The Western blot results are shown in Figure 2.

[0102] The results in Figure 2 show that the engineered strain GSΔoch1-PB0-His grew poorly. In the Western blot results of its 72-h fermentation broth sample, clear dimer bands can be seen, and monomer bands are also present. This indicates that in the PB0 dimer protein expressed by the engineered strain GSΔoch1-PB0-His, some dimers have broken down and monomers have been produced.

[0103] Example 6. Construction of GSΔoch1pAO strain

[0104] Based on the GSΔoch1 strain constructed in Example 4, the GSΔoch1pAO strain of the present application was constructed in the hope of obtaining a non-defective strain, thereby improving the growth of the strain; that is, by molecular biological means, the pAOαM vector (whose sequence is shown in SEQ ID NO: 10) containing the histidinol dehydrogenase gene (HIS4) was integrated into the defective HIS4 gene position of the yeast strain GSΔoch1, thereby achieving histidine deficiency complementation and obtaining the GSΔoch1pAO strain.

[0105] Specifically, the vector pAO containing the histidinol dehydrogenase encoding gene was linearized by SalI enzyme digestion, and the linearized DNA fragment was recovered; according to the method described in Example 2, the recovered linearized DNA fragment was electroporated into competent cells of the Pichia pastoris strain GSΔoch1 (as prepared in Example 4), and the solution in the electroporation cup was revived for 1 hour and then all applied to an SD culture dish (the culture medium in the SD culture dish was composed of: YNB 13.4 g / L, biotin 0.4 mg / L, glucose 20 g / L, agar powder 20 g / L), and the histidine-deficient complement strain was screened to obtain the GSΔoch1pAO engineered strain.

[0106] Example 7. Construction of a recombinant yeast strain producing SARS-CoV-2 PB0 protein based on the glycosylation engineered strain GSΔoch1pAO

[0107] According to the above-mentioned “Preparation of Pichia pastoris competent cells” procedure, competent cells of the GSΔoch1pAO strain were prepared; and, according to the procedure described in Example 2, a recombinant expression plasmid of the SARS-CoV-2 PB0 dimer (amino acid sequence and encoding nucleic acid sequence are the same as described in Example 2) was prepared, linearized, and electroporated into the competent cells of the GSΔoch1pAO strain to obtain the engineered strain of GSΔoch1pAO-PB0-His.

[0108] Example 8. Shake flask fermentation induction and protein expression detection of GSΔoch1pAO-PB0-His strain

[0109] According to the above-mentioned "shake flask fermentation induction of recombinant strains" procedure, two single clones of the engineered strain GSΔoch1pAO-PB0-His obtained in Example 7 were randomly selected and inoculated into BMMY medium to induce protein expression. Samples were taken every 24 h, and the OD value of the bacterial solution at 600 nm (i.e., OD 600 ), the strain growth curve is shown in Figure 3; at the same time, the fermentation broth was collected after 72 hours, the supernatant was collected, and the protein expression was detected according to the Western blot procedure in Example 5. The results are shown in Figure 3.

[0110] The results in Figure 3 show that compared with the engineered strain GSΔoch1-PB0-His (whose growth curve is shown in Figure 2), the growth of the strain GSΔoch1pAO-PB0-His was significantly improved; and, in the Western blot results of its 72-h fermentation broth sample, a clear, single dimer band can be seen, and a monomer band is also present; this indicates that the PB0 dimer protein expressed by the engineered strain GSΔoch1pAO-PB0-His is relatively single (including relatively uniform glycosylation modification), however, some dimer proteins are broken to form monomers (indicating that its expression is unstable).

[0111] Example 9. High-density fermentation induction of the engineered strain GSΔoch1pAO-PB0-His and acquisition of dimeric protein According to the above-mentioned “high-density fermentation induction of the recombinant strain” procedure, the engineered strain GSΔoch1pAO-PB0-His obtained in Example 7 was subjected to high-density fermentation, and, according to the method in Example 3, the purified RBD dimer protein PB0 was obtained, and its molecular sieve chromatography curve and SDS-PAGE identification results of its elution peak are shown in Figure 4.

[0112] As shown in Figure 4, two elution peaks, namely, peak 1 and peak 2, were generated during the molecular sieve chromatography process; the SDS-PAGE electrophoresis results of the two peaks showed that the eluate corresponding to peak 1 contained both dimer and monomer proteins, while the eluate corresponding to peak 2 contained only monomer proteins; this may be because: during molecular sieve chromatography, elution peak 1 and elution peak 2 corresponded to dimeric proteins and monomeric proteins, respectively. However, since the dimeric protein in elution peak 1 was unstable, some dimeric proteins broke to produce monomers after elution and before SDS-PAGE electrophoresis, thus forming a mixture of dimers and monomers. In short, high-density fermentation induction of the engineered strain GSΔoch1pAO-PB0-His failed to obtain a stable dimeric protein; N-terminal sequencing results confirmed that a break occurred between 328R / 329F of the PB0 dimer.

[0113] The above results indicate that the glycosylation of PB0 dimer is relatively uniform when expressed in the GSΔoch1pAO yeast system, thus the problem of heterogeneous glycosylation was solved by using this glycosylation-engineered strain. However, the monomer form appeared in the PB0 dimer, indicating that the PB0 dimer could not be stably expressed in the GSΔoch1pAO yeast system.

[0114] Example 10. Construction of recombinant yeast strains producing different prototype-Beta chimeric RBD dimer proteins based on the glycosylation engineered strain GSΔoch1pAO

[0115] In order to achieve stable expression of the dimeric protein, six different construction schemes were designed according to the break position. The specific construction schemes are shown in Figure 5A; in Figure 5A, PB represents the SARS-CoV-2 prototype-Beta chimeric RBD dimer (dimer of the RBD segment at positions 329-537), and GS, De, GSGS, DeGS, and R328-De are PB0 mutant sequences obtained by performing specific site mutations as shown in the figure on the basis of PB0; specifically, the amino acid sequence of the RBD dimer of PB is shown in SEQ ID NO: 1, and its encoding nucleic acid sequence is shown in SEQ ID NO: 2.

[0116] According to the design of Example 1, 6 recombinant expression plasmids were obtained respectively, and according to the procedures of the previous example, the recombinant expression plasmids were linearized and transformed into the strain GSΔoch1pAO to obtain the yeast engineering strains GS, De, GSGS, DeGS, R328-De, and PB.

[0117] Example 11. Detection of protein expression in engineered strains with different prototype-Beta chimeric RBD sequences at the shake flask level

[0118] Two clones were randomly selected from each of the engineered strains obtained in Example 10 and fermented in shake flasks according to the procedure described above for "Shake flask fermentation induction of recombinant strains." After 72 h of fermentation, the bacterial liquid was collected and centrifuged to obtain the supernatant. The expression of the dimer protein was detected by Western blot according to the procedure described in Example 5. The results are shown in Figure 5B.

[0119] As shown in Figure 5B, among the six engineered strains, the dimeric proteins expressed by the GS and De strains still show a large amount of fragmentation into monomers, the protein yields expressed by the GSGS and DeGS strains are extremely low, and the dimeric protein expressed by the R328-De strain still shows some fragmentation into monomers. In contrast, the expression of the PB strain is almost entirely dimeric protein, and the dimeric protein band is relatively clear and single (as indicated by the solid arrow), with high protein yield. This indicates that the PB engineered strain can stably express the dimeric protein PB (i.e., the dimer of the RBD segment at positions 329-537), and the expressed dimeric protein PB is uniform in form (including relatively uniform glycosylation modification) and high in yield.

[0120] Example 12. Obtaining a homogeneously glycosylated and stable dimeric prototype-Beta protein (PB)

[0121] According to the above-mentioned "High-density fermentation induction of recombinant strains" procedure, the engineered strain obtained in Example 11 was subjected to high-density fermentation, and according to the method in Example 3, the purified RBD dimer protein PB was obtained by Superdex™ 200 Increase 10 / 300GL molecular sieve. The molecular sieve chromatography curve and SDS-PAGE identification results of its elution peak are shown in Figure 6.

[0122] As shown in FIG6 , a stable PB dimer protein with uniform glycosylation (ie, a dimer of the RBD segment at positions 329-537) was obtained.

[0123] Example 13. Obtaining a uniformly glycosylated and stable dimeric Delta-Omicron (BA.1) protein (abbreviated as D-BA.1)

[0124] The method for constructing PB in Example 10 was used to construct an engineered strain D-BA.1 expressing Delta-Omicron (BA.1) RBD dimer protein, wherein the Delta-Omicron (BA.1) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (BA.1) variant, and its amino acid sequence is shown in SEQ ID NO: 3, and its encoding nucleic acid sequence is shown in SEQ ID NO: 4; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified, and its molecular sieve chromatography curve and SDS-PAGE identification results of its elution peak are shown in Figure 7; as can be seen from Figure 7, a stable, uniformly glycosylated D-BA.1 dimer protein was obtained.

[0125] As described above, the present application has developed a modified Pichia pastoris and a method for expressing the SARS-CoV-2 RBD dimer protein in the yeast strain to prepare a SARS-CoV-2 vaccine antigen. Using the modified Pichia pastoris strain, it is possible to achieve: (1) stable expression and high yield of specific RBD dimer protein antigens; (2) uniform glycosylation of the expressed antigen protein; (3) stable conformation of the antigen protein, which has strong application value as a vaccine antigen.

[0126] Because the epidemic variants of the new coronavirus change rapidly and some variants show strong immune escape, we used the above method to design a series of immunogens for vaccine preparation and experiments, proving the universality of this method.

[0127] Example 14. Detection of humoral immune response induced by RBD dimer protein

[0128] To test the immunogenicity of the various chimeric RBD-dimer proteins obtained in the above examples, we used the dimer proteins PB and D-BA.1 obtained in Examples 12 and 13 as immunogens to immunize BALB / c mice. The negative control (Sham group) was immunized with PBS solution, with 10 mice per group. The BALB / c mice used were purchased from Weitonglihua, all female, 6-8 weeks old. The mouse groups and immunization doses are shown in Table 1.

[0129] Table 1. Grouping and immunization dose of mice immunized with SARS-CoV-2 RBD dimer protein

[0130] The specific immunization procedure was as follows: the immunogen was diluted to 40 μg / ml in PBS and mixed with AddaVax adjuvant (a vaccine adjuvant similar to MF59) at a 1:1 volume ratio and emulsified to prepare the vaccine. A sham group was prepared by mixing PBS solution with AddaVax adjuvant to prepare the vaccine control. The resulting vaccine was administered intramuscularly to BALB / c mice. All mice received the first, second, and third immunizations on days 0, 21, and 42, respectively, with each 100 μL inoculation volume (containing 2 μg of antigen protein). On days 40 and 56, the mice were bled, and serum was collected by centrifugation and stored at -80°C.

[0131] The antigen-specific antibody titer induced by the vaccine in BALB / c mice was detected by ELISA. The specific detection procedure is as follows:

[0132] (1) Dilute the RBD of the new coronavirus to 3 μg / ml using ELISA coating solution (Solarbio, C1050). Add 100 μL of the corresponding RBD protein dilution solution to each well of a 96-well ELISA plate (Corning, 3590) and incubate at 4°C for 12 hours.

[0133] (2) Pour off the coating solution, add PBS, and wash once; use 5% skim milk prepared in PBS as blocking solution, add it to a 96-well plate, 100 μL per well, and leave it at room temperature for 1 hour for blocking; after blocking, wash once with PBS solution;

[0134] (3) During the blocking period, the immune mouse serum was diluted with blocking solution. Specifically, starting from 20 times, the serum was diluted in a 4-fold gradient. Then, 100 μL of diluent was added to each well of the ELISA plate. The negative control was added with blocking solution. The plates were incubated at 37°C for 2 hours and then washed 4 times with PBST (PBS containing 1 / 1000 Tween-20).

[0135] (4) Add HRP-conjugated goat anti-mouse secondary antibody (Abcam, ab6789) diluted 1:2000 with blocking solution, incubate at 37°C for 1.5 hours, then wash 5-6 times with PBST; add 60 μL TMB color development solution for color development, add 60 μL 2M hydrochloric acid after the reaction time is appropriate to terminate the reaction, and then measure the OD on the microplate reader. 450 Reading value;

[0136] The antibody titer was defined as the highest serum dilution at which the reaction value was greater than 2.5 times the negative control value. When the reaction value at the lowest dilution (detection limit) was still less than 2.5 times the background value, the titer of the sample was defined as half of the lowest dilution, i.e., 1:10.

[0137] The above-mentioned ELISA procedure was used to detect the antigen-specific antibody titers in the serum after the second immunization and the serum after the third immunization, and the results are shown in Figure 8; it can be seen from Figure 8 that the SARS-CoV-2 RBD dimers PB and D-BA.1 based on the modified Pichia pastoris of the present application can activate the body to produce higher levels of antibodies, especially after the third immunization, the antibody level is further enhanced.

[0138] Example 15. Neutralization assay of novel coronavirus pseudovirus to detect neutralizing antibody titers induced by vaccine in BALB / c mice

[0139] The 50% pseudovirus neutralization titer (pVNT) of the collected triple-immunized mouse sera against the pseudovirus of the prototype strain and variant strain of the new coronavirus was detected using the pseudovirus of the new coronavirus. 50 ), among which variants include Alpha, Beta, Delta, and Omicron variants.

[0140] The new coronavirus pseudovirus used in this example is a pseudovirus displaying the new coronavirus S protein prepared based on the vesicular stomatitis virus (VSV) backbone. For the preparation method, please refer to the method section of the paper published by this research group (Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant, N Engl J Med, 2022, PMID: 35081296).

[0141] The method for detecting the neutralizing antibody titer of the new coronavirus pseudovirus (hereinafter referred to as pseudovirus) is as follows:

[0142] In a 96-well plate, immune mouse serum was diluted in a 2-fold serial dilution series and then mixed with pseudovirus. At the same time, blank culture medium was mixed with pseudovirus as a control. The mixture was then incubated at 37°C for 1 hour. After that, the immune serum / blank culture medium-pseudovirus mixture was transferred to a 96-well plate filled with Vero cells. After 15 hours, the fluorescence value was calculated using a CQ1 confocal cell imager (Yokogawa). Then, a fitting curve was drawn in GraphPad Prism software to calculate the reciprocal of the serum dilution corresponding to 50% neutralization, which is the 50% pseudovirus neutralization titer (pVNT). 50 .

[0143] The results of the pseudovirus neutralizing antibody titer test for each immunogen are shown in FIG9 . As can be seen from FIG9 :

[0144] 1) Regarding the prototype and Beta chimeric RBD-dimer (PB), the geometric mean (GMT) of neutralizing antibody titers of sera from mice immunized with the prototype, Beta, Delta, Omicron BA.2, Omicron BA.1, and Omicron BA.5 pseudoviruses were 8972, 14056, 4817, 1172, 2510, and 117, respectively;

[0145] 2) Regarding the Delta and Omicron chimeric RBD-dimer (D-BA.1), the geometric mean (GMT) of the neutralizing antibody titers of the sera of mice immuned with the prototype strain pseudovirus, Beta strain pseudovirus, Delta strain pseudovirus, Omicron BA.2 strain pseudovirus, Omicron BA.1 strain pseudovirus and Omicron BA.5 strain pseudovirus were 8406, 10292, 26577, 19884, 46631 and 1800, respectively.

[0146] The above results show that the RBD dimer protein expressed by the recombinant Pichia pastoris engineered bacteria expressing the SARS-CoV-2 RBD dimer of the present application can induce the production of high levels of neutralizing antibody titers.

[0147] Example 16. Obtaining a uniformly glycosylated and stable dimeric Delta-Omicron (BA.5) protein (abbreviated as D-BA.5)

[0148] The method for constructing PB in Example 12 was used to construct an engineered strain D-BA.5 expressing the Delta-Omicron (BA.5) RBD dimer protein, wherein the Delta-Omicron (BA.5) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (BA.5) variant, and its amino acid sequence is shown in SEQ ID NO: 11, and its encoding nucleic acid sequence is shown in SEQ ID NO: 12; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified, and the SDS-PAGE identification results of the elution peak are shown in Figure 10; as can be seen from Figure 10, a stable, uniformly glycosylated D-BA.5 dimer protein was obtained.

[0149] Example 17. Obtaining the uniformly glycosylated and stable dimeric Delta-Omicron (BQ.1.1) protein (abbreviated as D-BQ.1.1)

[0150] The method for constructing PB in Example 12 was used to construct an engineered strain D-BQ.1.1 expressing the Delta-Omicron (BQ.1.1) RBD dimer protein, wherein the Delta-Omicron (BQ.1.1) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (BQ.1.1) variant, and its amino acid sequence is shown in SEQ ID NO: 13, and its encoding nucleic acid sequence is shown in SEQ ID NO: 14; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified, and the SDS-PAGE identification results of the elution peak are shown in Figure 11; as can be seen from Figure 11, a stable, uniformly glycosylated D-BQ.1.1 dimer protein was obtained.

[0151] Example 18. Obtaining a Uniformly Glycosylated and Stable Dimeric Delta-Omicron (XBB) Protein (abbreviated as D-XBB)

[0152] The method for constructing PB in Example 12 was used to construct an engineered strain D-XBB expressing the Delta-Omicron (XBB) RBD dimer protein, wherein the Delta-Omicron (XBB) RBD dimer is a dimer of the 329-537 RBD segment of the Delta variant and the 329-537 RBD segment of the Omicron (XBB) variant, whose amino acid sequence is shown in SEQ ID NO: 15 and whose encoding nucleic acid sequence is shown in SEQ ID NO: 16; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified, and the SDS-PAGE identification results of the elution peak are shown in Figure 12; as shown in Figure 12, a stable, uniformly glycosylated D-XBB dimer protein was obtained.

[0153] Example 19. Obtaining a Uniformly Glycosylated and Stable Dimeric Omicron(XBB)-Omicron(BA.5) Protein (Abbreviated as XBB-BA.5)

[0154] The method for constructing PB in Example 12 was used to construct an engineered strain XBB-BA.5 expressing the Omicron(XBB)-Omicron(BA.5)RBD dimer protein, wherein the Omicron(XBB)-Omicron(BA.5)RBD dimer is a dimer of the 329-537 RBD segment of the Omicron(XBB) variant and the 329-537 RBD segment of the Omicron(BA.5) variant, and its amino acid sequence is shown in SEQ ID NO: 17, and its encoding nucleic acid sequence is shown in SEQ ID NO: 18; then, according to the methods of Examples 11 and 12, the engineered strain was fermented and the protein was purified, and the SDS-PAGE identification results of the elution peak are shown in Figure 13; as shown in Figure 13, a stable, uniformly glycosylated XBB-BA.5 dimer protein was obtained.

[0155] Example 20. Detection of humoral immune response induced by RBD dimer protein

[0156] The humoral immune detection method in Example 14 was used to detect the immunogenicity of the chimeric RBD-dimer proteins obtained in Examples 16, 17, 18, and 19.

[0157] Specifically, the dimeric proteins D-BA.5, D-BQ.1.1, D-XBB, and XBB-BA.5 obtained in Examples 16, 17, 18, and 19 were used as immunogens to immunize BALB / c mice. A negative control (sham group) was immunized with a PBS solution plus AddaVax adjuvant. Eight mice were immunized in each group. The BALB / c mice used were purchased from Weitonglihua, all female, 6-8 weeks old. The mouse groups and immunization doses are shown in Table 2.

[0158] Table 2. Grouping and immunization dose of mice immunized with SARS-CoV-2 RBD dimer protein

[0159] Mice were immunized according to the immunization procedure in Example 14, and blood was collected on the 40th day (hereinafter referred to as "after the second immunization"), the 8th week (i.e., two weeks after the third immunization, hereinafter referred to as "after the third immunization"), and the 22nd week (i.e., 16 weeks after the third immunization, hereinafter referred to as "16 weeks after the third immunization") for future use.

[0160] The ELISA method described in Example 14 was used to detect the antigen-specific antibody titer induced by the vaccine in BALB / c mice.

[0161] The results of antigen-specific antibody titers in mouse serum after the second and third immunizations are shown in Figure 14; it can be seen from Figure 14 that the SARS-CoV-2 RBD dimers D-BA.5, D-BQ.1.1, D-XBB, and XBB-BA.5 based on the modified Pichia pastoris of the present application can activate the body to produce higher levels of binding antibodies, especially after the third immunization, the level of binding antibodies is further enhanced.

[0162] Example 21. Neutralization assay of novel coronavirus pseudovirus to detect neutralizing antibody titers induced by vaccine in BALB / c mice

[0163] The method described in Example 15 was used to detect the 50% pseudovirus neutralization titer (pVNT) of the collected mouse sera after three immunizations against the prototype strain and variant strains of the new coronavirus Beta, Delta, Omicron BA.2, Omicron BA.5, OmicronBF.7, Omicron BQ.1.1, Omicron XBB, Omicron EG.5.1 and Omicron BA.2.86 pseudoviruses. 50 ).

[0164] The results of the pseudovirus neutralizing antibody titer test for each immunogen are shown in FIG15 . As can be seen from FIG15 :

[0165] 1) Regarding the Delta and Omicron chimeric RBD-dimer (D-BA.5), the geometric mean (GMT) of neutralizing antibody titers of sera from mice immunized with the chimeric RBD-dimer against the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, Omicron BF.7 strain, Omicron BQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 strain, and Omicron BA.2.86 pseudovirus were 731, 533, 3808, 1176, 10311, 2602, 414, 54, 71, and 155, respectively;

[0166] 2) Regarding the Delta and Omicron chimeric RBD-dimer (D-XBB), the geometric mean (GMT) of neutralizing antibody titers of sera from mice immunized with the chimeric RBD-dimer against the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, Omicron BF.7 strain, Omicron BQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 strain, and Omicron BA.2.86 pseudovirus were 1438, 629, 3678, 969, 372, 474, 162, 1814, 322, and 731, respectively;

[0167] 3) Regarding the Delta and Omicron chimeric RBD-dimer (D-BQ.1.1), the geometric mean (GMT) of neutralizing antibody titers of sera from mice immunized with the chimeric RBD-dimer against the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, Omicron BF.7 strain, Omicron BQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 strain, and Omicron BA.2.86 strain pseudovirus were 569, 294, 4201, 2960, 12378, 8901, 20535, 48, 153, and 389, respectively;

[0168] 4) Regarding the Omicron (XBB) and Omicron (BA.5) chimeric RBD-dimer (XBB-BA.5), the geometric mean (GMT) of the neutralizing antibody titers of the immune mouse sera against the prototype strain, Beta strain, Delta strain, Omicron BA.2 strain, Omicron BA.5 strain, OmicronBF.7 strain, Omicron BQ.1.1 strain, Omicron XBB strain, Omicron EG.5.1 and Omicron BA.2.86 strain pseudovirus were 296, 174, 414, 4400, 19151, 20364, 7773, 3707, 1600 and 651, respectively.

[0169] Example 22. Neutralization assay of novel coronavirus pseudovirus to detect neutralizing antibody titers in serum of BALB / c mice 16 weeks after triple immunization induced by vaccine

[0170] The method described in Example 15 was used to detect the 50% pseudovirus neutralization titer (pVNT) of the sera collected 16 weeks after the three immunizations of the Sham, D-XBB and XBB-BA.5 groups against the prototype strains and variants of the new coronavirus Beta, Delta, Omicron BA.2, Omicron BA.5, Omicron BF.7, Omicron BQ.1.1, Omicron XBB, Omicron EG.5.1 and Omicron BA.2.86 pseudoviruses. 50 ).

[0171] The pseudovirus neutralizing antibody titer test results of the serum after three immunizations of the above-mentioned immunogens (corresponding to "8w" in the figure) and the serum 16 weeks after the three immunizations (corresponding to "22w" in the figure) are shown in Figure 16. It can be seen from Figure 16 that 16 weeks after the mice completed the three-injection sequential immunization, the pseudovirus neutralizing antibody titer levels of each immunogen were basically consistent with the titer levels of the serum after the three immunizations.

[0172] The above results show that the RBD dimer protein expressed by the recombinant Pichia pastoris expressing the SARS-CoV-2 RBD dimer of the present application induces the production of high levels of neutralizing antibodies, and this high level of neutralizing antibody titer can be maintained for a long time.

[0173] Example 23. Neutralizing Antibody Titers Induced by Yeast RBD Dimer Vaccine as a Booster in BALB / c Mice

[0174] To test the protective immune response of the yeast dimer RBD vaccine as a booster, we immunized BALB / c mice with the dimer proteins D-BA.5, D-XBB, and XBB-BA.5 obtained in Examples 16, 18, and 19. A negative control (sham group) was immunized with PBS solution plus AddaVax adjuvant. The BALB / c mice used were purchased from Weitonglihua, all female, 6-8 weeks old.

[0175] The specific immunization procedure is as follows: the vaccine is immunized in BALB / c mice by intramuscular injection. All mice receive the first, second, and third immunizations on days 0, 21, and 133, respectively. The first two injections are inactivated vaccines (BBIBP-CorV, Sinopharm Group China National Biotec Group Beijing Company), and the third injection (i.e., the booster injection) is the yeast-expressed dimer vaccine of this application, with an inoculation volume of 100 μL each time (containing 2 μg of antigen protein); the control group receives the third injection of inactivated vaccine. 2 weeks after the second immunization, 16 weeks after the second immunization, and 2 weeks after the third immunization, the mice are bled and the serum is collected by centrifugation. The obtained serum is stored in a refrigerator at -80°C.

[0176] The method described in Example 15 was used to detect the neutralization titer of the collected mouse serum after the second immunization against the pseudovirus of the new coronavirus prototype strain, and the 50% pseudovirus neutralization titer (pVNT) of the mouse serum after the third immunization against the pseudovirus of the new coronavirus prototype strain and variants Beta, Delta, Omicron BA.2, Omicron BA.5, Omicron BF.7, Omicron BQ.1.1, Omicron XBB, Omicron EG.5.1 and Omicron BA.2.86. 50 ).

[0177] The results of the neutralizing antibody titer test of mouse sera against the pseudovirus of the prototype strain of the new coronavirus 2 weeks and 16 weeks after the second immunization are shown in Figure 17. Figure 17 shows that after two injections of inactivated vaccine immunization, mice acquired the ability to protect against the pseudovirus of the prototype strain of the new coronavirus.

[0178] After boosting with the yeast-expressed dimer vaccine of the present application (i.e., three immunizations), the neutralizing antibody titer test results of mouse serum against the prototype strain and variant strains of the new coronavirus Beta, Delta, Omicron BA.2, Omicron BA.5, Omicron BF.7, Omicron BQ.1.1, Omicron XBB, Omicron EG.5.1 and Omicron BA.2.86 pseudoviruses are shown in Figure 18. Figure 18 shows that compared with the control group of three-dose inactivated vaccine, the use of ZF2001 (Anhui Zhifei Longcoma Biopharmaceutical Co., Ltd.) and yeast-expressed dimer vaccine as booster shots can not only improve the neutralizing ability against pseudoviruses but also increase the broad spectrum of neutralization against pseudoviruses, especially XBB-BA.5.

[0179] These results show that based on the basic immunity of inactivated vaccine, using the yeast-expressed dimer vaccine of this application as a booster shot can effectively improve the body's immune protection against the new coronavirus.

[0180] Example 24. Live poison challenge experiment

[0181] Experimental method: To evaluate the protective efficacy of the candidate vaccine XBB-BA.5, the SARS-CoV-2 challenge protection experiment used the epidemic mutant strain EG.5.

[0182] The experiment was divided into a Sham group and an XBB-BA.5 group, with 6 mice in each group, and the immunization method was shown in Table 2 above; the specific immunization scheme was as follows: a group of BALB / c mice (6-8 weeks old female, purchased from Weitonglihua) were immunized with PBS and XBB-BA.5, respectively, and three doses of 2 μg XBB-BA.5 vaccine (using AddaVax adjuvant) were vaccinated (with an interval of 21 days) according to the time nodes in Example 15. Serum was collected 2 weeks after the three immunizations for neutralizing antibody titer detection against Prototype, BA.5, BF.7, XBB, EG.5, and EG.5.1 pseudoviruses, and serum was collected 8 weeks after the three immunizations for neutralizing antibody titer detection against EG.5 pseudovirus. The detection method was referred to Example 21.

[0183] The results of the neutralizing antibody titer test against the above-mentioned pseudoviruses in the serum collected 2 weeks after the third immunization are shown in Figure 19. Figure 19 shows that compared with the Sham group, the neutralizing antibody levels against Prototype, BA.5, BF.7, XBB, EG.5, and EG.5.1 pseudoviruses in the serum of mice immunized with XBB-BA.5 were significantly increased, and the difference between the two was significant.

[0184] The results of the neutralizing antibody titer test against EG.5 pseudovirus in the serum collected 8 weeks after the third immunization are shown in Figure 20. Figure 20 shows that compared with the Sham group, the neutralizing antibody level against EG.5 pseudovirus in the serum of mice immunized with XBB-BA.5 was significantly increased, and the difference between the two was extremely significant.

[0185] Next, the Omicron EG.5 strain was used to challenge the immune mice with the novel coronavirus through intranasal administration. All challenge-related experiments were completed in an ABSL-3 laboratory. The challenge strain information and dose are as follows: Omicron EG.5 (NPRC 2.192100031) challenge dose was 2.5×10 4 TCID 50 On day 3 after challenge, mice were euthanized and lung tissue was collected from infected mice. The lung tissue was divided into two portions, one of which was placed in 4% paraformaldehyde for lung tissue section analysis. The remaining sample was stored at -80°C for subsequent RNA extraction and viral load determination.

[0186] Example 25. Determination of virus titer in lung tissue after challenge

[0187] In this example, RNA was extracted from the lung tissues of the XBB-BA.5 immunized mice and the Sham group mice after challenge with the live novel coronavirus in Example 24, and an RT-qPCR kit (Tiangen Biotech, China, Catalog No.: FP314) was used to perform SARS-CoV-2-specific quantitative PCR (qRT-PCR) on a CFX96 Touch real-time PCR detection system (Bio-Rad, USA). Specifically, a specific region of the N gene and a specific sequence of the E gene of the viral genome were detected (for details, please see Chandrashekar, A., et al., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020. 369(6505): p. 812-817).

[0188] RNA extraction (ABSL-3 laboratory):

[0189] The lung sample was ground, and 200 μL of the supernatant was added to the lysis buffer (500 μL) of the RNA extraction kit and mixed well to inactivate the virus. RNA was then extracted according to the instructions of the MagaBio plus viral RNA extraction kit; the extracted RNA was stored in a -80°C refrigerator for later use.

[0190] (1) qPCR experiment: The following primers and probes (Table 3) were used to detect the gRNA and sgRNA levels of the viral genome of Omicron EG.5; gRNA represents the load of the infected virus, and sgRNA represents the load of the replicating virus;

[0191] Table 3. qPCR primer and probe sequences

[0192] According to Tables 4 and 5 below, configure the qPCR system and set the qPCR program.

[0193] Table 4. qPCR system configuration

[0194] Table 5. qPCR program

[0195] The qPCR detection results of viral gRNA and sgRNA in mouse lung samples are shown in Figure 21; Figure 21 shows that the levels of viral gRNA and sgRNA in the lungs of the XBB-BA.5 immunized mouse group were significantly lower than those in the PBS group, and the sgRNA of the immunized mice was even below the detection line, indicating that the XBB-BA.5 vaccine completely inhibited the replication of the virus.

[0196] From the above experimental results, it can be concluded that XBB-BA.5 as an immunogen can effectively reduce the viral load in the lungs of mice immunized with live virus challenge experiments, and at the same time can inhibit the replication of the virus, showing a good protective effect against the popular new coronavirus variant EG.5.

[0197] Example 26. Histopathological analysis of lungs after challenge

[0198] In this example, the mouse lung tissue collected in Example 25 was fixed, dehydrated, paraffin-embedded, and sliced; the tissue sections (4 μm) were dewaxed in xylene and stained with hematoxylin and eosin (HE) for pathological examination.

[0199] The results are shown in Figure 22. As shown in Figure 22, mice immunized with the XBB-BA.5 vaccine showed milder pneumonia symptoms, with reduced lung hemorrhage and inflammatory cell infiltration, indicating that the vaccine has a good protective effect on mice.

[0200] Example 27. Electron microscopy structure analysis of the PB and CB6 Fab complex

[0201] The PB dimer protein prepared in Example 12 was mixed with the CB6 Fab protein and incubated at 4°C for 2 hours. Molecular sieve chromatography (pH 7.4) was then performed using a Superdex™ 200 Increase 10 / 300GL column (GE Healthcare). The eluted peak was characterized by SDS-PAGE. The SDS-PAGE results indicated that the eluted peak was a complex of the PB protein and the CB6 Fab. This confirmed that a complex protein of the PB dimer protein and the CB6 Fab was obtained. This sample was used for electron microscopy structural analysis.

[0202] Prepare the Quantifoil grid (specification 1.2 / 1.3) for sample preparation in advance and perform glow discharge hydrophilization treatment.

[0203] The prepared PB dimer protein and CB6 Fab complex was then dripped onto the prepared grid. The grid was then rapidly immersed in liquid ethane using a Vitrobot Mark IV automated sample preparation machine. Data were collected using a 300 kV Titan Krios transmission electron microscope (Thermo Fisher Scientific) equipped with a K3 direct electron detector camera. Numerous images were acquired using the Serial-EM automated acquisition program. The raw data were then drift-corrected using MotionCor2 software, and contrast transfer function correction was performed using CTFFIND4.1 software. Further image processing and final 3D reconstruction were performed using Relion-3.1 software.

[0204] The cryo-electron microscopy of the complex of PB dimer and CB6 Fab is shown in Figure 23. As can be seen from Figure 23, the PB dimer appears to be approximately "double lung-shaped", in which the Prototype RBD can bind to CB6 Fab, which shows that the PB dimer protein can expose important immune epitopes, thereby stimulating the specific immune response of mice.

[0205] Example 28. Preparation of PB0 and PB protein N carbohydrate mass spectrometry samples

[0206] Appropriate amounts of PB0 protein samples expressed by wild-type yeast (as prepared in Example 3) and PB protein samples expressed by the glycosylation engineered strain GSΔoch1pAO (as prepared in Example 12) were taken, and an appropriate amount of N-glycosidase (PNGaseF) was added. The samples were placed in a 37°C water bath overnight to release N-glycans. 500uL of a 5% acetonitrile solution containing 0.01% trifluoroacetic acid was then added to the sample mixture. The N-glycans in the mixture were extracted using a solid-phase extraction method based on porous graphitized carbon (PGC). After foramidation derivatization, the derivatized N-glycans were purified using a solid-phase extraction method based on hydrophilic chromatography. The purified N-glycans were detected in the positive ion mode of a MALDI-TOF-MS mass spectrometer. The N-glycans were first dissolved in 10uL of a 50% acetonitrile solution. A 0.5 μL sample was spotted onto a small well on a stainless steel MALDI plate. The same volume of 10 mg / mL DHB matrix containing 10 mM sodium acetate was then spotted to ensure that the glycans were ionized as sodium adducts. Based on the mass of the N-glycans, 1000 laser shots were performed at a laser frequency of 2000 Hz. The detection mass range was set to 1000–3000 Da, with 1000 laser shots per sample. Mass spectrometry data were baseline corrected, noise filtered, and peak deisotoped using Data Explorer software (Applied Biosystems).

[0207] The N-glycan mass spectrometry results of PB0 and PB proteins are shown in Figure 24, and the corresponding percentage analysis results are shown in Figure 25. Figures 24 and 25 show that PB0 has a relatively broad glycan structure (i.e., man4-man16), with the main glycoside types being man9 and man10, accounting for 33.81% and 36.3%, respectively; while PB protein has a narrower glycan structure (i.e., man6-man15), with the main glycoside types being man8 and man9, accounting for 46.29% and 24.85%, respectively. This indicates that, compared to PB0 protein expressed in the wild-type yeast strain, PB protein expressed in the glycosylation-engineered strain GSΔoch1pAO can effectively reduce the number of glycan types and increase the uniformity of protein glycosylation modification.

[0208] In summary, the recombinant Pichia pastoris engineered bacteria expressing the SARS-CoV-2 RBD dimer of the present application can not only efficiently express uniformly glycosylated and stable SARS-CoV-2 RBD dimer proteins, but the expressed RBD dimer proteins can also induce strong humoral immune responses and produce high levels of neutralizing antibody titers, which has great cost-effectiveness and practical significance.

[0209] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit them. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the present application. Industrial Applicability

[0210] The modified Pichia pastoris strain provided in the present application can not only express and secrete recombinant proteins at high levels, but also improve the glycosylation modification of the recombinant proteins expressed therefrom; the recombinant Pichia pastoris engineered bacteria expressing the novel coronavirus antigen based on the modified Pichia pastoris strain can efficiently express uniformly glycosylated, high-quality RBD dimer antigens, and the expressed RBD dimer antigens can be used as immunogens to induce the body to produce high-level neutralizing antibodies against multiple mutant strains of the novel coronavirus, and are a potential broad-spectrum vaccine for the novel coronavirus.

[0211] Sequences involved in this application:

[0212] Amino acid sequence of PB (SEQ ID NO: 1)

[0213] PB encoding nucleic acid sequence (SEQ ID NO: 2)

[0214] Amino acid sequence of D-BA.1 (SEQ ID NO: 3)

[0215] The encoding nucleic acid sequence of D-BA.1 (SEQ ID NO: 4)

[0216] pMPICZα sequence (SEQ ID NO: 5)

[0217] Amino acid sequence of PPO (SEQ ID NO: 6)

[0218] The encoding nucleic acid sequence of PPO (SEQ ID NO: 7)

[0219] Amino acid sequence of PB0 (SEQ ID NO: 8)

[0220] The encoding nucleic acid sequence of PBO (SEQ ID NO: 9)

[0221] pAOαM recombinant expression plasmid sequence containing histidinol dehydrogenase gene (HIS4) (SEQ ID NO: 10)

[0222] Amino acid sequence of D-BA.5 (SEQ ID NO: 11)

[0223] The encoding nucleic acid sequence of D-BA.5 (SEQ ID NO: 12)

[0224] Amino acid sequence of D-BQ.1.1 (SEQ ID NO: 13)

[0225] The encoding nucleic acid sequence of D-BQ.1.1 (SEQ ID NO: 14)

[0226] Amino acid sequence of D-XBB (SEQ ID NO: 15)

[0227] The encoding nucleic acid sequence of D-XBB (SEQ ID NO: 16)

[0228] Amino acid sequence of XBB-BA.5 (SEQ ID NO: 17)

[0229] XBB-BA.5 encoding nucleic acid sequence (SEQ ID NO: 18)

[0230] gRNA-F (SEQ ID NO: 19)

[0231] gRNA-probe (SEQ ID NO: 20)

[0232] gRNA-R (SEQ ID NO: 21)

[0233] sgRNA-F (SEQ ID NO: 22)

[0234] sgRNA-probe(SEQ ID NO:23)

[0235] sgRNA-R(SEQ ID NO:24)

Claims

1. A modified Pichia pastoris strain, characterized in that: The modified Pichia pastoris strain is obtained by knocking out the α-1,6-mannosyltransferase gene and complementing the histidine deficiency on the basis of the Pichia pastoris GS115 strain.

2. The method for preparing the modified Pichia pastoris strain according to claim 1, characterized in that: The preparation method comprises the following steps: (1) By genetic engineering, the α-1,6-mannosyltransferase gene in the Pichia pastoris GS115 strain was knocked out to obtain the GS115Δoch1 strain; (2) After linearizing the exogenous histidinol dehydrogenase expression plasmid, the plasmid was integrated into the GS115Δoch1 strain to obtain the modified Pichia pastoris strain.

3. A recombinant Pichia pastoris engineered bacterium, characterized in that: The recombinant Pichia pastoris engineered bacteria is obtained by introducing the coding sequence of the SARS-CoV-2 S protein RBD antigen into the modified Pichia pastoris strain as described in claim 1.

4. The recombinant Pichia pastoris engineered bacterium according to claim 3, characterized in that: The novel coronavirus S protein RBD antigen is a homozygous or chimeric dimer of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variant strain; Among them, the SARS-CoV-2 variants are selected from: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Omicron subtype BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, BA.4, BA.5, BQ.1.1, and XBB.

5. The recombinant Pichia pastoris engineered bacterium according to claim 4, characterized in that: The novel coronavirus S protein RBD antigen is a dimer formed by the 329-537 amino acid fragments of the S protein RBD region of the SARS-CoV-2 prototype strain and / or its variant strain through a linker or directly connected in series, preferably a dimer formed by directly connecting in series; Preferably, the novel coronavirus S protein RBD antigen is a dimer formed by directly connecting the 329-537 amino acid fragments of the S protein RBD region of the prototype strain and the prototype strain, the prototype strain and the Beta variant, the Beta variant and the Delta variant, the Delta variant and the Omicron variant, or the Omicron variant and the Omicron variant. Further preferably, the dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of the Delta variant and the Omicron variant is selected from: a dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of Delta and Omicron BA.1, Delta and Omicron BA.4, Delta and Omicron BA.5, Delta and Omicron XBB, Delta and Omicron BQ.1.1; and / or, the dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of the Omicron variant and the Omicron variant is selected from: a dimer formed by directly concatenating the amino acid fragment at positions 329-537 of the S protein RBD region of Omicron XBB and Omicron BQ.1.1, Omicron XBB and Omicron BA.

5.

6. The recombinant Pichia pastoris engineered bacterium according to claim 5, characterized in that: The novel coronavirus S protein RBD antigen is selected from: (1) A two-mer peptide consisting of the amino acid fragments 329-537 of the S protein RBD region of the prototype strain and the Beta variant strain directly connected A polymer, whose amino acid sequence is shown in SEQ ID NO: 1, preferably, which is encoded by the nucleotide sequence shown in SEQ ID NO: 2; (2) a dimer formed by directly connecting the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.1 in series, wherein the amino acid sequence is as shown in SEQ ID NO:3, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO:4; (3) a dimer formed by directly connecting the amino acid fragment 329-537 of the RBD region of the S protein of Delta and Omicron BA.5 in series, wherein the amino acid sequence is as shown in SEQ ID NO: 11, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 12; (4) a dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron BQ.1.1 in series, wherein the amino acid sequence is as shown in SEQ ID NO: 13, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 14; (5) a dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Delta and Omicron XBB in series, wherein the amino acid sequence is as shown in SEQ ID NO: 15, and preferably, it is encoded by the nucleotide sequence as shown in SEQ ID NO: 16; (6) A dimer formed by directly connecting the amino acid fragment 329-537 of the S protein RBD region of Omicron XBB and Omicron BA.5 in series, wherein the amino acid sequence is shown in SEQ ID NO: 17, and preferably, it is encoded by the nucleotide sequence shown in SEQ ID NO:

18.

7. The method for preparing the recombinant Pichia pastoris engineered bacteria according to any one of claims 3 to 6, characterized in that: The preparation method comprises the following steps: The coding sequence of the SARS-CoV-2 S protein RBD antigen is cloned into a Pichia pastoris expression vector to obtain a recombinant expression plasmid; after linearization, the obtained recombinant expression plasmid is transferred into the modified Pichia pastoris strain as described in claim 1 to obtain the recombinant Pichia pastoris engineered bacteria.

8. The preparation method according to claim 7, characterized in that: The Pichia pastoris expression vector comprises the following elements: a promoter, an α-mating factor signal, a Kex2 protease recognition site, a multiple cloning site, a C-terminal His tag, and a terminator; optionally, the promoter is an AOX promoter; optionally, the terminator is an AOX terminator; Preferably, the Pichia pastoris expression vector is selected from: Escherichia coli-Pichia pastoris shuttle expression vector pMPICZα, pPICZαA, pPICZαB, pPICZαC, pPIC9K, PichiaPink, preferably pMPICZα, whose nucleic acid sequence is shown in SEQ ID NO: 5; Optionally, the linearized recombinant expression plasmid is transferred into the modified Pichia pastoris strain as claimed in claim 1 by electroporation; Preferably, the preparation method comprises: 1) Clone the coding sequence of the novel coronavirus S protein RBD antigen into a Pichia pastoris expression vector, preferably an Escherichia coli E. coli-Pichia pastoris shuttle expression vector pMPICZα to obtain the recombinant expression plasmid; 2) linearizing the recombinant expression plasmid obtained in step 1) by enzyme digestion; 3) preparing competent cells of the modified Pichia pastoris strain as claimed in claim 1; 4) The linearized recombinant expression plasmid obtained in step 2) is transferred into the competent cells obtained in step 3) by electroporation to obtain the recombinant Pichia pastoris engineered bacteria.

9. Use of the recombinant Pichia pastoris engineered bacteria as described in any one of claims 3 to 6 in the preparation of a recombinant protein vaccine for the new coronavirus.

10. A method for preparing a recombinant protein vaccine of a novel coronavirus, characterized in that: The method comprises: fermenting and culturing the recombinant Pichia pastoris engineered bacteria as described in any one of claims 3 to 6, collecting the supernatant, and isolating the expressed SARS-CoV-2 S protein RBD antigen therefrom.

Citation Information

Patent Citations

  • Pichia pastoris underglycosylated mutant strain and application of pichia pastoris underglycosylated mutant strain

    CN105087405A

  • Preparation method and application of coronavirus S protein RBD glycoprotein

    CN113754739A

  • New coronavirus Delta and Omicron variant chimeric antigen as well as preparation method and application thereof

    CN114634556A

  • Compositions for administration of different doses of RNA

    WO2023067193A2